Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0E8NP
|
||||
| Former ID |
DNCL003449
|
||||
| Drug Name |
Birinapant
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
TetraLogic Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C42H56F2N8O6
|
||||
| InChI |
InChI=1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1
|
||||
| InChIKey |
PKWRMUKBEYJEIX-DXXQBUJASA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | X-linked inhibitor of apoptosis protein | Target Info | Modulator | [532662], [532682] | |
| Inhibitor of apoptosis protein 2 | Target Info | Modulator | [532662], [532682] | ||
| KEGG Pathway | NF-kappa B signaling pathway | ||||
| Ubiquitin mediated proteolysis | |||||
| Apoptosis | |||||
| Focal adhesion | |||||
| Toxoplasmosis | |||||
| HTLV-I infection | |||||
| Pathways in cancer | |||||
| Small cell lung cancerhsa04064:NF-kappa B signaling pathway | |||||
| Hippo signaling pathway | |||||
| NOD-like receptor signaling pathway | |||||
| TNF signaling pathway | |||||
| Small cell lung cancer | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| Reactome | SMAC binds to IAPs | ||||
| SMAC-mediated dissociation of IAP:caspase complexes | |||||
| Deactivation of the beta-catenin transactivating complex | |||||
| RIPK1-mediated regulated necrosis | |||||
| Regulation of TNFR1 signaling | |||||
| TNFR1-induced NFkappaB signaling pathway | |||||
| Regulation of necroptotic cell deathR-HSA-111465:Apoptotic cleavage of cellular proteins | |||||
| NOD1/2 Signaling Pathway | |||||
| TNFR2 non-canonical NF-kB pathway | |||||
| Regulation of necroptotic cell death | |||||
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | |||||
| IKK complex recruitment mediated by RIP1 | |||||
| References | |||||
| Ref 524774 | ClinicalTrials.gov (NCT02147873) Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL. U.S. National Institutes of Health. | ||||
| Ref 542455 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7432). | ||||
| Ref 532662 | cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood. 2014 Apr 17;123(16):2562-72. | ||||
| Ref 532682 | Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-?B activation, and is active in patient-derived xenograft models. Mol Cancer Ther. 2014 Apr;13(4):867-79. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.